A Prescription for Saving Big DrugmakersMark Schneider
Shares in traditional "Big Pharma" drug companies have fallen on hard times. After outperforming other stocks for decades, they have lagged the market in recent years. The pharmaceutical business is still one of the most profitable industries in the U.S. But concerns over patent expirations of blockbuster drugs, generic drug competition, regulatory problems, and a lack of promising new products are giving investors caution. Significant drug price increases did not help the drugmakers' public perception, and President Obama's health-care reform plans might limit future prospects.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.